Live Breaking News & Updates on Adalimumab

Stay updated with breaking news from Adalimumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Using TNF inhibitors during pregnancy not associated with worse fetal or obstetric outcomes

According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477). ....

France General , Megan Craig , American College Of Rheumatology , American College , Anna Molto , Cochin Hospital , Inflammatory Arthritis , Tumor Necrosis Factor ,

Biosimilar Administration Considerations Impacting Patient Experience

Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications. ....

Bincy Abraham , Ryan Haumschild , Jamiet Brogan , Aliceb Gottlieb , Vibeke Strand , Citrate Free Standard , Citrate Free Pen , Dose Optimizing , Injection Site Pain , Il 17 Blocker ,

Switching with Adalimumab Biosimilar Maintains Benefit for Plaque Psoriasis

Trial data support multiple switching between biosimilar and reference product over a 48-week course for the treatment of psoriasis. ....

Baylor Scott White , Alan Menter , Drug Administration , Baylor Scott , Psoriasis Area Severity Index , Global Physicians Assessment , Plaque Psoriasis , Phase 3 ,